ARGX - Stock Analysis & Overview

About argenx SE

Biotechnology

Healthcare

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study...

argenx SE Key Metrics

Market Cap: $32B
52 Weeks Low: $327.73
52 Weeks High: $554.74
P/B: 7.37x
P/E: -118.13x
P/S: 15.70x

Upcoming Events

ARGX Analyst Forecasts

‌

ARGX Financials

ARGX Income Statement Key Metrics

Revenue(TTM)2.02 B
Gross Profit(TTM)1.69 B
EBITDA(TTM)-299.65 M
Net Income(TTM)-266.04 M
EPS Diluted(TTM)-4.54

Decode ARGX's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

ARGX earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of ARGX (0.904) is higher than the average of its peers (0.526).

Net Profit Margin vs Peers

Net profit margin ratio of ARGX (-0.241) is higher than the average of its peers (-0.729).

ARGX Return on Equity

See how efficiently ARGX generates profit for it's shareholders.

-7.20%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of ARGX (-0.072) is higher than the average of its peers (-0.333).

Return on Equity Growth

ARGX's Return on Equity has shown poor growth over the past 10 years, increasing by only -9.97%.

ARGX Revenue Growth

See how ARGX has grown it's revenue over the past 10 years.

‌

Revenue Growth

ARGX's revenue has grown significantly over the past 10 years, increasing by over 74.94%.

argenx SE

Page title

Section title